Company Participants
Diane Weiser – Senior Vice President of Corporate Affairs
Robert I. Blum – CEO, President & Director
Fady Malik – Executive Vice President of Research & Development
Andrew Callos – Executive VP & Chief Commercial Officer
Conference Call Participants
Zaki Molvi – Jefferies LLC, Research Division
Tessa Romero – JPMorgan Chase & Co, Research Division
Roanna Clarissa Ruiz – Leerink Partners LLC, Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
Salim Syed – Mizuho Securities USA LLC, Research Division
Mario Joshua Chazaro Cortes – Evercore ISI Institutional Equities, Research Division
Jason Butler – Citizens JMP Securities, LLC, Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Martin Auster – Raymond James & Associates, Inc., Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division
Serge Belanger – Needham & Company, LLC, Research Division
Maxwell Skor – Morgan Stanley, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Mayank Mamtani – B. Riley Securities, Inc., Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Jason Zemansky – BofA Securities, Research Division
Presentation
Operator
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to Cytokinetics conference call for the FDA approval of MYQORZO. [Operator Instructions].
At this time, I would like to turn the call over to Diane Weiser, Cytokinetics’ Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Affairs
Good afternoon, and thanks for joining us on today’s call to discuss the FDA approval of MYQORZO for symptomatic obstructive HCM. Today, I’m joined by my colleagues, Robert Blum, President and CEO, who will provide introductory
Credit: Source link
